|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pilot Study in Patients With Head and Neck Cancer Finds That Derma Sciences, Inc. (DSCI)' MEDIHONEY® Reduces Hospital Stays in the U.K.
9/21/2012 9:44:36 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported an independent pilot study conducted in the U.K. showed that MEDIHONEY® may reduce the length of hospital stays by encouraging more rapid healing. The study, entitled “Randomised controlled feasibility trial on the use of medical grade honey following microvascular free tissue transfer to reduce the incidence of wound infection,” was conducted by Dr. Val Robson, RGN, B.Sc (Hons) Dip HE, Clinical Nurse Specialist Leg Ulcer Care, and colleagues from University Hospital Aintree, Liverpool, U.K. The article was published in the British Journal of Oral and Maxillofacial Surgery in June 2012.
|
|
|
|
|
|
|
|
|
|
|